{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.61","value":"-2.8"},{"groupId":"OG001","spread":"0.61","value":"-4.0"},{"groupId":"OG002","spread":"0.63","value":"-3.5"}]}],"title":"Change from Baseline at Week 4 [N=60; 60; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.65","value":"-3.9"},{"groupId":"OG001","spread":"0.65","value":"-5.1"},{"groupId":"OG002","spread":"0.68","value":"-4.9"}]}],"title":"Change from Baseline at Week 8 [N=61; 61; 56]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.76","value":"-4.2"},{"groupId":"OG001","spread":"0.74","value":"-4.9"},{"groupId":"OG002","spread":"0.80","value":"-5.4"}]}],"title":"Change from Baseline at Week 12 [N=58; 60; 53]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.73","value":"-3.9"},{"groupId":"OG001","spread":"0.73","value":"-4.8"},{"groupId":"OG002","spread":"0.75","value":"-5.5"}]}],"title":"Change from Baseline at EOT [N=62; 61; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"Male lower urinary tract symptoms were assessed by the ICIQ MaleLUTS questionnaire which consists of 13 questions each on a 0-4 scale (larger scores correspond to worse conditions). The total symptom score ranges from 0 to 52.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 4, 8 and 12","title":"Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}